Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lowered by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.0% in the 3rd quarter, Holdings Channel.com reports. The fund owned 10,330 shares of the biopharmaceutical company’s stock after selling 2,742 shares during the quarter. UNIVEST FINANCIAL Corp’s holdings in Regeneron Pharmaceuticals were worth $7,833,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Western Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $26,000. Armstrong Advisory Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 466.7% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 28 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $29,000. Trust Co. of Vermont purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $29,000. Finally, Fiduciary Financial Advisors purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $29,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 4.7%

NASDAQ:REGN opened at $959.41 on Thursday. The company has a market cap of $99.25 billion, a PE ratio of 21.18, a price-to-earnings-growth ratio of 1.21 and a beta of 0.10. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a 50 day simple moving average of $811.95 and a two-hundred day simple moving average of $745.49. Regeneron Pharmaceuticals, Inc. has a 12 month low of $591.52 and a 12 month high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company’s revenue was up 36.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.83 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.30%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on REGN. Raymond James Financial upped their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Evercore lifted their price objective on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Bank of America lifted their price objective on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $660.00 to $978.00 in a research report on Thursday, October 15th. Finally, Argus upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price on the stock in a research note on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $898.97.

Key Regeneron Pharmaceuticals News

Investors following REGN have been watching these news items:

• Positive Sentiment: Regeneron collaborator Alnylam reported first-in-human results for CIDEBsiRNA in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD). A single dose rapidly normalized liver fat and improved markers of liver injury, providing encouraging early evidence for a potential treatment opportunity. Article: Alnylam collaborator Regeneron advances CIDEBsiRNA with promising first-in-human results
• Positive Sentiment: Soleo Health was selected as a specialty-pharmacy partner for Pasatru (garetosmab), Regeneron’s recently approved treatment for adults with the rare disorder fibrodysplasia ossificans progressiva. The partnership may support the drug’s distribution and patient access, although no sales impact was specified. Article: Soleo Health selected as a specialty pharmacy partner for Pasatru
• Neutral Sentiment: A Zacks article characterized REGN as a long-term value stock, but the summary provided no new company-specific developments or valuation details that would clearly explain near-term trading. Article: Why Regeneron is a top value stock for the long term

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 7,830 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the completion of the sale, the director directly owned 5,219 shares in the company, valued at $5,057,680.71. The trade was a 60.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Andrew J. Murphy sold 4,147 shares of the business’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the sale, the insider owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 27,028 shares of company stock valued at $25,025,950 in the last 90 days. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.